Latin America Bladder Cancer Therapeutics & Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The market is segmented by Cancer Type, Therapeutics and Diagnostics, and Geography.

Market Snapshot

Study Period: 2018 - 2026
Base Year: 2020
CAGR: 3.4 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Based on the data from the International Agency for Research on Cancer, bladder cancer is the 6th most commonly diagnosed cancer of males and the 9th leading cause of cancer deaths worldwide. As per the data from the World Health Organization (2018), the number of new cases of Bladder cancer in Brazil was 9,127 which is around 3.3% of the total cancers that occurred in 2018.

In recent years, the awareness regarding bladder diseases and their management has drastically improved, particularly in developing regions such as Latin America. Also, the rise of different therapies such as immunotherapy in cancer treatment has rekindled interest among eligible patients as it is a recently developed treatment modality, and has lower side effects when compared to radiation therapy and chemotherapy, which are conventional therapeutic options in bladder cancer management.

Hence, the increasing awareness about bladder cancer and related therapies, the Latin America bladder cancer therapeutics and diagnostics market is expected to grow in the coming future. Apart from this, factors like increasing healthcare expenditure and innovations in novel drug development are also contributing to the growth of this market.

Scope of the Report

Bladder cancer is a urologic malignancy arising from the epithelial lining of the urinary bladder. Bladder cancer therapeutics are procedures that inhibit and stunt the growth or kill the cancer cells. Diagnostics techniques include methods that help in the diagnosis of bladder cancer.

In the report, a detailed analysis of the bladder cancer therapeutics and diagnostics market in Latin America is provided. The market is evaluated by collating revenues generated across segments, categorized by Cancer Type, by Therapeutics and Diagnostics, and Geography.

By Cancer Type
Transitional Cell Bladder Cancer
Superficial Bladder Cancer
Invasive Bladder Cancer
Squamous Cell Bladder Cancer
Other Rare Types
By Therapeutics and Diagnostics
By Therapeutics
Radiation Therapy
By Diagnostics
Urine Ctyology
Bladder Ultrasound
Latin America (LATAM)
Rest of Latin America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Radiation Therapy is Expected to Cover a Large Share of the Market

Bladder cancer is highly prevalent and increases with age. As per a 2016 report by Cancer Research UK, the incidence of bladder cancer increases with age. Moreover, the geriatric population in Latin America countries is expected to increase in the future as per a 2017 report by the United Nations titled "World Population Ageing" 2017. This factor is expected to increase the number of bladder cancer patients in future.

The most advanced modalities of bladder cancer therapeutics include immunotherapy but, the most widely used modality in bladder cancer is radiation therapy. This is due to historical use-prevalence of radiation therapies in various forms of cancers and also because chemotherapy is associated with low specificity and side-effects. Radiation therapy also, offers best in class efficacy, in terms of dose frequency and pricing, when compared to other therapeutic modalities in bladder cancer management. Advancements in radiation therapy and expected increase in number of bladder cancer patients is expected to help the growth of this market.


Competitive Landscape

The Latin America bladder cancer market is moderately competitive and majorly dominated by the global players. With the rising technology and focus of various companies on the drug discovery, it has been believed that several new companies will be entering the market in the coming future and are expected to hold a significant market share.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Awareness about Bladder Diseases, and Available Therapies

      2. 4.2.2 Increasing Healthcare Expenditure

      3. 4.2.3 Innovations in Drug Development

    3. 4.3 Market Restraints

      1. 4.3.1 Rise in the number of Patent Expirations

      2. 4.3.2 Asymptomatic Nature of the Disease

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Cancer Type

      1. 5.1.1 Transitional Cell Bladder Cancer

      2. 5.1.2 Superficial Bladder Cancer

      3. 5.1.3 Invasive Bladder Cancer

      4. 5.1.4 Squamous Cell Bladder Cancer

      5. 5.1.5 Other Rare Types

    2. 5.2 By Therapeutics and Diagnostics

      1. 5.2.1 By Therapeutics

        1. Chemotherapy

        2. Immunotherapy

        3. Radiation Therapy

        4. Surgery

      2. 5.2.2 By Diagnostics

        1. Cytoscopy

        2. Biopsy

        3. Urinalysis

        4. Urine Ctyology

        5. Bladder Ultrasound

    3. 5.3 Geography

      1. 5.3.1 Latin America (LATAM)

        1. Mexico

        2. Brazil

        3. Argentina

        4. Rest of Latin America


    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca Plc.

      2. 6.1.2 Bristol Myers Squibb

      3. 6.1.3 Celgene Corporation

      4. 6.1.4 Eli Lilly and Co.

      5. 6.1.5 GlaxoSmithKline Plc.

      6. 6.1.6 Merck & Co., Inc.

      7. 6.1.7 Johnson and Johnson

      8. 6.1.8 Novartis AG

      9. 6.1.9 Pfizer Inc.

      10. 6.1.10 Sanofi S.A.

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Latin America Bladder Cancer Therapeutics & Diagnostics Market market is studied from 2018 - 2026.

The Latin America Bladder Cancer Therapeutics & Diagnostics Market is growing at a CAGR of 3.4% over the next 5 years.

Pfizer Inc, Johnson and Johnson, AstraZeneca Plc., Bristol Myers Squibb, Merck & Co Inc are the major companies operating in Latin America Bladder Cancer Therapeutics & Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!